Akari Therapeutics Plc(AKTX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.6M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
AKTX Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Akari Therapeutics Plc (AKTX), a Healthcare sector company. AKTX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.6m in revenue and is scored on the micro-cap board instead. Top institutional holders of AKTX by reported 13-F value include MMCAP International SPC, Cresset Asset Management, JANE STREET GROUP, based on the most recent SEC filings. AKTX trades on the Nasdaq exchange and files with the SEC under CIK 1541157. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AKTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Akari Therapeutics Plc directly from SEC EDGAR.
Net Income
Q2 2026
$-4.8M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
+12.6% YoYOperating Income
+20.2% YoYEPS (Diluted)
Total Assets
-5.3% YoYOp. Cash Flow
+15.8% YoYFree Cash Flow
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $367.9K -39.5% | $607.7K | — | — |
| Net Income | $-17.3M +12.6% | $-19.8M -97.8% | $-10.0M +43.6% | $-17.7M -1.9% | $-17.4M -2.0% | $-17.1M |
| Operating Income | $-17.3M +20.2% | $-21.6M -28.8% | $-16.8M +27.2% | $-23.1M -34.1% | $-17.2M +4.3% | $-18.0M |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 +100.0% | $-0.01 |
| Total Assets | $47.9M -5.3% | $50.6M +1061.0% | $4.4M -68.5% | $13.8M +18.7% | $11.6M -20.2% | $14.6M |
| Operating Cash Flow | $-10.6M +15.8% | $-12.6M +23.6% | $-16.4M +23.6% | $-21.5M -14.1% | $-18.8M -11.2% | $-17.0M |
| Free Cash Flow | — | — | $-16.4M +24.1% | $-21.6M | — | — |
Get alerted when AKTX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Akari Therapeutics Plc including:
Top Institutional Holders of AKTX
MMCAP International Inc. SPC
$1.0M100,000 shCresset Asset Management, LLC
$210.6K20,561 shJANE STREET GROUP, LLC
$158.4K15,463 shHRT FINANCIAL LP
$140.0K13,745 shCITADEL ADVISORS LLC
$102.5K10,000 shIFP Advisors, Inc
$1.9K181 shSBI Securities Co., Ltd.
$143.0014 shCaitong International Asset Management Co., Ltd
$82.008 shNORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
$72.007 shTruvestments Capital LLC
$10.001 sh
| Fund | Value | Shares |
|---|---|---|
| MMCAP International Inc. SPC | $1.0M | 100,000 |
| Cresset Asset Management, LLC | $210.6K | 20,561 |
| JANE STREET GROUP, LLC | $158.4K | 15,463 |
| HRT FINANCIAL LP | $140.0K | 13,745 |
| CITADEL ADVISORS LLC | $102.5K | 10,000 |
| IFP Advisors, Inc | $1.9K | 181 |
| SBI Securities Co., Ltd. | $143.00 | 14 |
| Caitong International Asset Management Co., Ltd | $82.00 | 8 |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | $72.00 | 7 |
| Truvestments Capital LLC | $10.00 | 1 |
More Healthcare Companies
View all Healthcare →Put AKTX on your watchlist
Track score changes the day Akari Therapeutics Plc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is AKTX a good stock to buy?
13F Pro's AI-powered analysis of Akari Therapeutics Plc (AKTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AKTX are available on the AKTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. AKTX is classified as a mega company.
Which hedge funds own AKTX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AKTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Akari Therapeutics Plc's investment landscape.